Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions

Ta Chiang Liu, David Kirn

Research output: Contribution to journalReview articlepeer-review

100 Scopus citations

Abstract

Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.

Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalCancer research
Volume67
Issue number2
DOIs
StatePublished - Jan 15 2007

Fingerprint

Dive into the research topics of 'Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions'. Together they form a unique fingerprint.

Cite this